- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03103958
Effects of Probiotic on Modulation of the Intestinal Microbiota in Constipated Patients
Phase IV, Double Blind, Randomized, Study Between Probiatop and Placebo for the Assessment of Improving the Gastrointestinal Function and Intestinal Bacterial Flora in Constipated Patients
Study Overview
Status
Intervention / Treatment
Detailed Description
It is a double-blind, randomized, placebo control study that evaluated the action of a probiotic in relation to a placebo in the human intestinal microbiome by the technique of metagenomics, as well as evaluated the effects of this probiotic on the gastrointestinal transit of constipated participants.
One hundred and twenty constipated patients will be randomized into two groups:Probiatop or Placebo. The first 22 patients from each group will also perform a metagenomic evaluation through the stool sample collection before and after of treatment. Besides these procedures, all patients will fill out a symptom assessment questionnaire at baseline of the study, and then after 14 and 28 days after the beginning of the treatment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Agree to adhere to the procedures and requirements of the study and attend the institute on the day (s) and time (s) determined for the evaluations;
- Being able to consent study participation
Have one or more complaints of change in bowel habits in the last 3 months with onset of symptoms at least 6 months before diagnosis, as described below:
- Evacuation effort for at least 25% of defecations
- Lumpy stools, on sausage-shaped or hardened in at least 25% of stools, according to the Bristol scale. number 1, 2 or 3;
- Incomplete evacuation count in at least 25% of defecations;
- Feeling of anorectal obstruction / blockage of feces in at least 25% of defecations;
- Manufactured manuals to facilitate at least 25% of stools (for example, evacuation with digital help, pelvic floor support)
Exclusion Criteria:
- Pregnancy or breast-feeding;
- Known intolerance or allergy to any of the study products;
- Previous history of gastrointestinal surgery;
- Patients with celiac disease or inflammatory bowel disease;
- Patients with psychiatric, cardiologic, respiratory, renal and hepatic disease;
- No acceptance of study admission by the participant; Diagnosis of Clostridium difficile diarrhea in the last 3 months;
- Patients with known immunosuppressive disease;
- Any other gastrointestinal pathology;
- Prior use of antibiotics in less than 30 days;
- Frequent use of laxatives or other medication that alters bowel motility (one week without Use before inclusion)
- Regular treatment with probiotics / symbiotic, including regular use of yogurt with probiotics (One week before use before inclusion)
- Regular use of antidepressant, opioid analgesic, antispasmodic or anticholinergic agents
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: probiotic
Probiotic consists of Lactobacillus acidophilus NCFM, Lactobacillus rhamnosus HN001, Lactobacillus paracasei LPC-37 and Bifidobacterium lactis HN019 (Probiatop), Subjects will take two sachets per day after diluting them in 100 ml of water for 28 days.
|
Probiatop is a live microbial preparation saches containing 1g of the formulation composed by Lactobacillus acidophilus NCFM, 10⁹, Lactobacillus rhamnosus HN001 10⁹, Lactobacillus paracasei LPC-37 10⁹, Bifidobacterium lactis HN019 10⁹ combined with Polydextrose. Subjects will take two sachets per day after diluting them in 100 ml of water
Other Names:
|
Placebo Comparator: Placebo
Placebo consists of maltodextrin.
Subjects will take two sachets per day after diluting them in 100 ml of water for 28 days.
|
The placebo sachets were prepared by substituting equivalent amounts of Maltodextrin for the probiotic powder. Subjects will take two sachets per day after diluting them in 100 ml of water |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Increased number of bowel movements
Time Frame: 28 days
|
Participants will record the number of defecations per day in a daily diary during the study
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Adverse events
Time Frame: 28 days
|
Participants will record the adverse events in a daily diary during study
|
28 days
|
Changes of intestinal bacteria flora
Time Frame: 28 days
|
Quantitative analysis of the participants' microbiota bacteria by sequencing the 16S rDNA gene and the readings obtained from each participant werw compared with genomic banks for identification of the microorganism.
|
28 days
|
Improve the quality of life of participants evaluated through quality of life questionnaire
Time Frame: 28 days
|
The evaluation was performed through quality of life questionnaire.
|
28 days
|
Evaluation of symptoms of constipation
Time Frame: 28 days
|
Improvement of symptoms of constipation by criteria and Bristol scale
|
28 days
|
Improvement of symptoms of constipation
Time Frame: 28 days
|
Improvement of symptoms of constipation by ROME III
|
28 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Ludmila Donato, Monitor, FQM
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FE4-PROBIATOP-PA-14
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Constipation
-
usMIMA S.L.CompletedConstipation | Constipation Chronic Idiopathic | Constipation; NeurogenicSpain, United Kingdom
-
AbbVieIronwood Pharmaceuticals, Inc.RecruitingFunctional Constipation (FC) | Chronic Idiopathic Constipation (CIC)United States, United Kingdom, Bulgaria, Netherlands
-
usMIMA S.L.University of York; County Durham and Darlington NHS Foundation TrustNot yet recruitingConstipation | Constipation-predominant Irritable Bowel Syndrome | Constipation - Functional | Constipation Chronic Idiopathic | Constipation; Neurogenic
-
Institute of Medical Sciences and SUM HospitalNot yet recruitingFunctional Constipation | Constipation - Functional | Constipation Chronic Idiopathic | Fecal Impaction | Pediatric Functional ConstipationIndia
-
SK Life Science, Inc.CompletedChronic Constipation | Functional ConstipationUnited States
-
Cairo UniversityUnknownChronic Idiopathic Constipation | Functional ConstipationEgypt
-
ProgenaBiomeRecruitingConstipation | Constipation - Functional | Constipation Chronic Idiopathic | Constipation (Excl Faecal Impaction)United States
-
Pamukkale UniversityRecruiting
-
Shanghai University of Traditional Chinese MedicineLonghua Hospital; Shanghai Municipal Hospital of Traditional Chinese MedicineRecruiting
-
Universidade Nova de LisboaCINTESIS - Center for Health Technology and Services ResearchRecruiting
Clinical Trials on Probiotic
-
King's College Hospital NHS TrustCompleted
-
Fudan UniversityInner Mongolia Yili Industrial Group Co., LtdCompletedObesity | AdiposityChina
-
Maastricht University Medical CenterCompleted
-
Centros de Investigación de Nutrición y SaludNutribioticaCompletedFunctional ConstipationSpain
-
Universiti Kebangsaan Malaysia Medical CentreUnknownHypertension | Obesity | Type 2 Diabetes Mellitus | HyperlipidemiaMalaysia
-
BiocodexCompletedAcute GastroenteritisArgentina
-
Fundació Sant Joan de DéuCompleted
-
University of LeedsUnknown
-
Centro Pediatrico Albina de PatinoCompletedAcute Gastroenteritis | Acute DiarrheaBolivia
-
Shandong UniversityUnknownGastrointestinal Neoplasms | Colorectal Cancer | Malnutrition | Effects of Chemotherapy | Tumor ImmunityChina